Efavirenz Outperforms Boosted Atazanavir among Treatment-Naive HIV-1-Infected Persons in Routine Clinical Care

Efavirenz Outperforms Boosted Atazanavir among Treatment-Naive HIV-1-Infected Persons in Routine Clinical Care

Background: Effectiveness of antiretroviral therapy (ART) in a routine clinical care may result different from the clinical trials. We assessed the virologic outcomes in treatment-naive persons who received either efavirenz (EFV) or atazanavir/ritonavir (ATV/r) with a backbone of tenofovir/emtricita...

Full description

Bibliographic Details
Main Authors:	Toshibumi Taniguchi MD, Jessica R. Grubb MD, Diana Nurutdinova MD, Nur F. Önen MD, Enbal Shacham PhD, Michael Donovan BS, Edgar Turner Overton MD
Format:	Article
Language:	English
Published:	SAGE Publishing 2013-03-01
Series:	Journal of the International Association of Providers of AIDS Care
Online Access:	https://doi.org/10.1177/1545109712467057

Similar Items

The Relationship of Social Support and Neighborhood Perceptions among Individuals with HIV
by: Enbal Shacham PhD, et al.
Published: (2017-09-01)

Psychiatric Diagnoses among an HIV-Infected Outpatient Clinic Population
by: Enbal Shacham PhD, et al.
Published: (2016-03-01)

Virologic outcomes on dolutegravir-, atazanavir-, or efavirenz-based ART in urban Zimbabwe: A longitudinal study.
by: Tinei Shamu, et al.
Published: (2024-01-01)

Virologic outcomes on dolutegravir-, atazanavir-, or efavirenz-based ART in urban Zimbabwe: A longitudinal study
by: Tinei Shamu, et al.
Published: (2024-01-01)

HIV-Tat Exacerbates the Actions of Atazanavir, Efavirenz, and Ritonavir on Cardiac Ryanodine Receptor (RyR2)
by: Fadhel A. Alomar, et al.
Published: (2022-12-01)

Serum Lipid Profiles of Patients Taking Efavirenz-Based Antiretroviral Regimen Compared to Ritonavir-Boosted Atazanavir with an Optimized Background at Zewditu Memorial Hospital, Addis Ababa, Ethiopia
by: Muche Belete A, et al.
Published: (2021-02-01)

Body weight and blood pressure changes on dolutegravir‐, efavirenz‐ or atazanavir‐based antiretroviral therapy in Zimbabwe: a longitudinal study
by: Tinei Shamu, et al.
Published: (2024-02-01)

Boosting the Brain Delivery of Atazanavir through Nanostructured Lipid Carrier-Based Approach for Mitigating NeuroAIDS
by: Saif Ahmad Khan, et al.
Published: (2020-11-01)

Prevalence and correlates of persistent intracellular HIV transcription in individuals on efavirenz versus atazanavir-based regimens: A prospective cohort study.
by: Dimitrios Pilalas, et al.
Published: (2018-01-01)

Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients
by: Tony Antoniou, et al.
Published: (2017-04-01)

Ritonavir-boosted darunavir is rarely associated with nephrolithiasis compared with ritonavir-boosted atazanavir in HIV-infected patients.
by: Takeshi Nishijima, et al.
Published: (2013-01-01)

Is ritonavir-boosted atazanavir a risk for cholelithiasis compared to other protease inhibitors?
by: Yohei Hamada, et al.
Published: (2013-01-01)

Niveles de perfil lipídico en pacientes con VIH-sida en tratamiento con efavirenz y atazanavir. Estudio de cohorte
by: Fernando Geldres-Molina, et al.
Published: (2021-10-01)

Substantial Effect of Efavirenz Monotherapy on Bilirubin Levels in Healthy Volunteers
by: Ingrid F. Metzger, PhD, et al.
Published: (2014-12-01)

Pharmacologic boosting of atazanavir in maintenance HIV-1 therapy: the COREYA propensity-score adjusted study.
by: Laurent Hocqueloux, et al.
Published: (2012-01-01)

Results of a comparative study of the efficacy of once daily darunavir/atazanavir in treatment-naïve patients with HIV infection
by: G F Moshkovich, et al.
Published: (2014-11-01)

External validation of the bilirubin-atazanavir nomogram for assessment of atazanavir plasma exposure in HIV-1-infected patients.
by: Rekić, D, et al.
Published: (2013)

A Machine Learning Algorithm Outperforms Traditional Multiple Regression to Predict Risk of Unplanned Overnight Stay Following Outpatient Medial Patellofemoral Ligament Reconstruction
by: Chimere O. Ezuma, B.S., et al.
Published: (2022-06-01)

Role of atazanavir in the treatment of HIV infection
by: Pablo Rivas, et al.
Published: (2008-12-01)

Prospective evaluation of bone markers, parathormone and 1,25-(OH)<sub>2 </sub>vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz
by: Focà Emanuele, et al.
Published: (2012-02-01)

Metabolic and kidney disorders correlate with high atazanavir concentrations in HIV-infected patients: is it time to revise atazanavir dosages?
by: Cristina Gervasoni, et al.
Published: (2015-01-01)

Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study
by: Rebecca Zash, MD, et al.
Published: (2018-07-01)

Efavirenz in pregnancy
by: Polly Clayden, et al.
Published: (2010-11-01)

Alpha Defensin-1 Biomarker Outperforms Culture in Diagnosing Breast Implant-related Infection: Results from a Multicenter Prospective Study
by: Marten Basta, MD, et al.
Published: (2021-10-01)

Giant annular lichenoid drug eruption caused by efavirenz therapy
by: Emily Baumrin, MD, et al.
Published: (2018-04-01)

PLANNING AND EVALUATION OF BIOEQUIVALENCE STUDIES OF ATAZANAVIR PRODUCTS
by: N. E. Uvarova, et al.
Published: (2018-12-01)

Conflicting effects of atazanavir therapy on atherosclerotic risk factors in stable HIV patients: A randomized trial of regimen switch to atazanavir.
by: Joshua A Beckman, et al.
Published: (2017-01-01)

Artificial neural networks outperform linear regression in estimating 9-month patient-reported outcomes after upper extremity fractures with increasing number of variables
by: Niels Brinkman, BS, et al.
Published: (2024-01-01)

Pharmacogenetic Associations Between Atazanavir/UGT1A1*28 and Efavirenz/rs3745274 (CYP2B6) Account for Specific Adverse Reactions in Chilean Patients Undergoing Antiretroviral Therapy
by: Daniela Poblete, et al.
Published: (2021-05-01)

Total Hip Arthroplasty Outperforms Hemiarthroplasty in Patients Aged 65 Years and Older: A Propensity-Matched Study of Short-Term Outcomes
by: Jared A. Warren DO, et al.
Published: (2019-09-01)

Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study
by: Ling Xu, et al.
Published: (2021-01-01)

Short-term cost analysis of raltegravir versus atazanavir + ritonavir or darunavir + ritonavir for treatment-naive adults with HIV-1 infection in the United States.
by: Anita J Brogan, et al.
Published: (2018-01-01)

Efavirenz-induced urolithiasis.
by: Wirth, G, et al.
Published: (2006)

Efavirenz and neuropsychiatric effects
by: Mukesh Dheda
Published: (2017-04-01)

3-T MRI Outperforms 1.5-T MRI in Diagnosis of Osteochondral Lesions of the Talus in Patients Undergoing Broström Repair
by: Kirsten N. Mansfield, et al.
Published: (2022-11-01)

Spectrum of Atazanavir-Selected Protease Inhibitor-Resistance Mutations
by: Soo-Yon Rhee, et al.
Published: (2022-05-01)

Atazanavir Crystal–Induced Chronic Granulomatous Interstitial Nephritis
by: Vipin Varghese, et al.
Published: (2020-07-01)

Incidence of neuropsychiatric side effects of efavirenz in HIV-positive treatment-naïve patients in public-sector clinics in the Eastern Cape
by: Razia Gaida, et al.
Published: (2016-06-01)

Correction: Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral-Therapy-Naive Patients Infected with HIV-1.
Published: (2004-12-01)

Correction to: Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study
by: Ling Xu, et al.
Published: (2021-02-01)